Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

412

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

October 8, 2021

Study Completion Date

October 22, 2021

Conditions
Corona Virus InfectionSars-CoV2
Interventions
DIETARY_SUPPLEMENT

Vitamins

2 tablets daily from the first day (day 0) to day 9

DRUG

Telmisartan

1 tablet daily from the first day (day 0) to day 9

DRUG

Ciclesonide

2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9

DRUG

interferon β-1b

A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water

Trial Locations (7)

33000

Bordeaux university Hospital, Bordeaux

34295

CHU de Montpellier, Montpellier

75014

Groupe hospitalier Paris Saint Joseph, Paris

Unknown

CHU de Dijon-Bourgogne, Dijon

CHRU de Nancy, Nancy

CNGE, Paris

CHU de Toulouse, Toulouse

All Listed Sponsors
collaborator

University of Bordeaux

OTHER

lead

University Hospital, Bordeaux

OTHER

NCT04356495 - Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation | Biotech Hunter | Biotech Hunter